IL196897A - Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet - Google Patents

Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet

Info

Publication number
IL196897A
IL196897A IL196897A IL19689709A IL196897A IL 196897 A IL196897 A IL 196897A IL 196897 A IL196897 A IL 196897A IL 19689709 A IL19689709 A IL 19689709A IL 196897 A IL196897 A IL 196897A
Authority
IL
Israel
Prior art keywords
cyclohexylpiperazin
piperadine
chlorothiophen
thiazol
carbamoyl
Prior art date
Application number
IL196897A
Other languages
English (en)
Hebrew (he)
Other versions
IL196897A0 (en
Inventor
Robert E Desjardins
Rudolph Lucek
Original Assignee
Akarx Inc
Robert E Desjardins
Rudolph Lucek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarx Inc, Robert E Desjardins, Rudolph Lucek filed Critical Akarx Inc
Publication of IL196897A0 publication Critical patent/IL196897A0/en
Publication of IL196897A publication Critical patent/IL196897A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL196897A 2006-08-08 2009-02-04 Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet IL196897A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83633406P 2006-08-08 2006-08-08
PCT/US2007/017860 WO2008021283A2 (en) 2006-08-08 2007-08-08 Compositions and methods for increasing blood platelet levels in humans

Publications (2)

Publication Number Publication Date
IL196897A0 IL196897A0 (en) 2011-08-01
IL196897A true IL196897A (en) 2015-08-31

Family

ID=39082656

Family Applications (4)

Application Number Title Priority Date Filing Date
IL196897A IL196897A (en) 2006-08-08 2009-02-04 Preparations based on 1- (3-Chloro-5 - {[4- (4-Chloro-Ophen-2-Il) -5- (4-Cyclohexylpiperazine-1-Il) Thiazole-2-Il] Carbamoyl} Pyridine-2-Il ) Carboxylic acid or salts, to increase levels of human platelet
IL240323A IL240323A (en) 2006-08-08 2015-08-03 Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
IL240322A IL240322A0 (en) 2006-08-08 2015-08-03 Preparations based on 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazio-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl Piperadine-4-carboxylic acid or salts, to increase levels of platelets in human blood
IL245911A IL245911A0 (en) 2006-08-08 2016-05-29 Compositions and methods for increasing the level of blood platelets in humans

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL240323A IL240323A (en) 2006-08-08 2015-08-03 Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
IL240322A IL240322A0 (en) 2006-08-08 2015-08-03 Preparations based on 1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazio-1-yl)thiazol-2-yl]carbamoyl}pyridin-2-yl Piperadine-4-carboxylic acid or salts, to increase levels of platelets in human blood
IL245911A IL245911A0 (en) 2006-08-08 2016-05-29 Compositions and methods for increasing the level of blood platelets in humans

Country Status (8)

Country Link
US (2) US20080039475A1 (OSRAM)
EP (2) EP2056826B1 (OSRAM)
JP (3) JP2010500361A (OSRAM)
AU (2) AU2007284644B2 (OSRAM)
CA (1) CA2660283C (OSRAM)
ES (2) ES2452032T3 (OSRAM)
IL (4) IL196897A (OSRAM)
WO (1) WO2008021283A2 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2314586B1 (en) * 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
WO2011019990A1 (en) * 2009-08-14 2011-02-17 Eisai, Inc. Use of e5501 for stimulating platelet production
CN112022825B (zh) * 2020-08-24 2024-03-22 瑞阳制药股份有限公司 马来酸阿伐曲泊帕片剂及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5330998A (en) * 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
US5256675A (en) * 1989-08-07 1993-10-26 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP0620403B1 (de) * 1993-04-08 1996-12-04 ABB Management AG Misch- und Flammenstabilisierungseinrichtung in einer Brennkammer mit Vormischverbrennung
WO1996028447A1 (en) * 1995-03-09 1996-09-19 Kyowa Hakko Kogyo Co., Ltd. Pyrrolocarbazole derivatives
KR19990008109A (ko) * 1995-04-28 1999-01-25 나가사까 겐지로 1,4-이치환 피페리딘 유도체
CZ291749B6 (cs) * 1995-06-07 2003-05-14 Glaxo Group Limited Peptidová sloučenina, která se váže na thrombopoetinový receptor a aktivuje jej a farmaceutický prostředek
US5963666A (en) * 1995-08-18 1999-10-05 International Business Machines Corporation Confusion matrix mediated word prediction
ES2195016T3 (es) * 1995-10-17 2003-12-01 Daiichi Suntory Pharma Co Ltd Medicamento contra la trombocitopenia.
US5932546A (en) * 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
CA2337755C (en) * 1998-09-18 2008-07-29 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6498155B1 (en) * 1998-11-17 2002-12-24 Smithkline Beecham Corporation Methods of treating thrombocytopenia
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
US7199124B2 (en) * 2001-02-02 2007-04-03 Takeda Pharmaceutical Company Limited JNK inhibitor
WO2002062775A1 (en) * 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or its salt
EP2314586B1 (en) * 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
EP1531815B1 (en) * 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
WO2004029049A1 (ja) * 2002-09-30 2004-04-08 Yamanouchi Pharmaceutical Co., Ltd. 2-アシルアミノチアゾール誘導体の新規な塩
JP2006524688A (ja) * 2003-03-25 2006-11-02 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール
EP1647553A4 (en) * 2003-07-17 2008-12-31 Astellas Pharma Inc 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF
CA2535511C (en) * 2003-08-12 2009-11-17 Shionogi And Co., Ltd. Compounds having thrombopoietin receptor agonism
JP2009514941A (ja) * 2005-11-08 2009-04-09 アステラス製薬株式会社 血小板減少症を治療する化合物および方法

Also Published As

Publication number Publication date
IL240323A (en) 2016-05-31
EP2452674A3 (en) 2012-05-30
JP6258264B2 (ja) 2018-01-10
IL245911A0 (en) 2016-07-31
EP2452674B1 (en) 2014-03-26
US20080039475A1 (en) 2008-02-14
IL196897A0 (en) 2011-08-01
AU2011253775A1 (en) 2011-12-22
CA2660283A1 (en) 2008-02-21
IL240322A0 (en) 2015-09-24
EP2056826A2 (en) 2009-05-13
JP2013047257A (ja) 2013-03-07
WO2008021283A2 (en) 2008-02-21
JP2015221806A (ja) 2015-12-10
IL240323A0 (en) 2015-09-24
AU2007284644B2 (en) 2011-09-01
HK1170673A1 (en) 2013-03-08
EP2056826A4 (en) 2009-09-09
US20110224226A1 (en) 2011-09-15
AU2011253775B2 (en) 2014-02-13
ES2452032T3 (es) 2014-03-31
WO2008021283A3 (en) 2008-12-11
AU2007284644A1 (en) 2008-02-21
EP2452674A2 (en) 2012-05-16
JP2010500361A (ja) 2010-01-07
ES2470333T3 (es) 2014-06-23
CA2660283C (en) 2014-11-18
EP2056826B1 (en) 2014-01-08

Similar Documents

Publication Publication Date Title
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
NO2020032I1 (no) Avatrombopag and pharmaceutically acceptable salts thereof, particularly avatrombopag maleate (1-(3-chloro-5-{[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl) thiazol-2-yl] carbamoyl} pyridin-2-yl) piperidine-4-carboxylic acid maleic acid salt
EP1973595A4 (en) ACTIVE CANNULA FOR BIOMASS AND SURGICAL INTERVENTIONS
MX2009013272A (es) Formas amorfas estabilzadas de mesilato de imatinib.
TN2009000317A1 (en) Solid preparation comprising alogliptin and pioglitazone
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
WO2007093450A3 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
IL194744A (en) Derivatives 1– (alkyl) –3– (amino-converted) –5– (converted) - s-triazole, a process for their preparation and pharmacological preparations containing them for the treatment of psychotic diseases
WO2009007411A3 (fr) Inhibition de la formation des ages
WO2009150118A3 (en) Novel salts of (4-{[(5-{[(3-chlorophenyl)methyl]oxy}-2-methylphenyl)carbonyl]amino}-3-methylphenyl)acetic acid
BR112012003462A2 (pt) "composto, composição farmacêutica, e, método para tratar um paciente tendo uma condição mediada pela proteína quinase."
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
WO2007116025A3 (en) Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
IL240323A (en) Preparations based on 1 - (3-chloro-5 - {[4- (4-chloro-phenyl-2-ram) -5- (4-cyclohexylpiperazine-1-ram) thiazole-2-ram] carbamoyl} pyridine-2-ram ) Carboxylic acid or salts, to increase levels of human platelet
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
IL201959A (en) Annals 2 - (1-Acetyl-Piperidine-4-Il) -4,2- Dihydro-Pyrazole-3-On
WO2011098799A3 (en) Respiratory disease treatment
WO2008065123A3 (en) Polymorphic forms of deferasirox ( icl670a)
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
TW200800993A (en) Organic compounds
MX2012000466A (es) Metodo y composiciones farmaceuticas para el tratamiento de la hiperglicemia postprandial de la diabetes tipo ii, a traves de la mucosa bucal.
WO2007104933A8 (en) Chemical compounds
WO2009136884A3 (en) Metformin-pioglitazone formulation with antihyperglycemic effects
WO2007138233A3 (fr) Utilisation du zatosetron pour le traitement de la rosacee
WO2008050698A3 (en) Agent for prophylaxis or treatment of alcohol dependence or drug dependence

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed